

Transarterial Chemoembolization of Unresectable Hepatocellular Carcinoma with Drug-Eluting Beads: Results of an Open-Label Study of 62 Patients

CardioVascular and Interventional Radiology

31, 269-280

DOI: 10.1007/s00270-007-9226-z

Citation Report

#	ARTICLE	IF	CITATIONS
1	Transarterial Chemoembolization for Hepatocellular Carcinoma with Drug-Eluting Microspheres: Preliminary Results from an Italian Multicentre Study. CardioVascular and Interventional Radiology, 2008, 31, 1141-1149.	2.0	112
3	Drug-eluting particles in the treatment of HCC: chemoembolization with doxorubicin-loaded DC Beadâ„¢. Expert Review of Anticancer Therapy, 2008, 8, 1643-1650.	2.4	44
4	Optimal Strategies for Combining Transcatheter Arterial Chemoembolization and Radiofrequency Ablation in Rabbit VX2 Hepatic Tumors. Journal of Vascular and Interventional Radiology, 2008, 19, 1740-1748.	0.5	49
5	TACE versus TAE as therapy for hepatocellular carcinoma. Expert Review of Anticancer Therapy, 2008, 8, 1623-1641.	2.4	78
6	Evidence-based diagnosis and locoregional therapy for hepatocellular carcinoma. Expert Review of Gastroenterology and Hepatology, 2008, 2, 761-784.	3.0	14
7	Regional therapies for treatment of intermediate-stage hepatocellular carcinoma. , 0, , 66-96.		0
8	Transcatheter Chemoembolization of Unresectable Hepatocellular Carcinoma: Current Knowledge and Future Directions. Digestive Diseases, 2009, 27, 157-163.	1.9	29
9	Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma After Attempted Portal Vein Embolization in 25 Patients. American Journal of Roentgenology, 2009, 193, W446-W451.	2.2	18
10	DC Beadâ„¢: a major development in the toolbox for the interventional oncologist. Expert Review of Medical Devices, 2009, 6, 389-400.	2.8	56
12	Unusual Severe Complication Following Transarterial Chemoembolization for Metastatic Malignant Melanoma: Giant Intrahepatic Cyst and Fatal Hepatic Failure. CardioVascular and Interventional Radiology, 2009, 32, 361-364.	2.0	6
13	Analysis of Nontarget Embolization Mechanisms During Embolization and Chemoembolization Procedures. CardioVascular and Interventional Radiology, 2009, 32, 615-622.	2.0	37
15	Transarterial therapies in HCC: Does embolization increase survival?. Journal of Hepatology, 2009, 51, 981-983.	3.7	6
16	Arterial Chemoembolization/Embolization and Early Complications after Hepatocellular Carcinoma Treatment: A Safe Standardized Protocol in Selected Patients with Child Class A and B Cirrhosis. Journal of Vascular and Interventional Radiology, 2009, 20, 896-902.	0.5	33
17	Drug eluting beads in the treatment of liver cancer. , 2010, , 154-189.		1
18	Chemoembolization for Primary and Metastatic Liver Cancer. Cancer Journal (Sudbury, Mass), 2010, 16, 156-162.	2.0	33
19	Intra-Arterial Therapies for Hepatocellular Carcinoma: Where Do We Stand?. Annals of Surgical Oncology, 2010, 17, 1234-1246.	1.5	80
20	Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V Study. CardioVascular and Interventional Radiology, 2010, 33, 41-52.	2.0	1,329
21	Prospective Randomized Comparison of Chemoembolization with Doxorubicin-Eluting Beads and Bland Embolization with BeadBlock for Hepatocellular Carcinoma. CardioVascular and Interventional Radiology, 2010, 33, 541-551.	2.0	331

#	ARTICLE	IF	CITATIONS
22	Contrast-Enhanced Ultrasonography of Hepatocellular Carcinoma After Chemoembolisation Using Drug-Eluting Beads: A Pilot Study Focused on Sustained Tumor Necrosis. CardioVascular and Interventional Radiology, 2010, 33, 1022-1027.	2.0	25
23	Unenhanced and Contrast-Enhanced Ultrasonography During Hepatic Transarterial Embolization and Chemoembolization With Drug-Eluting Beads. CardioVascular and Interventional Radiology, 2010, 33, 1215-1222.	2.0	16
24	Simple liquid chromatography method for the quantification of irinotecan and SN38 in sheep plasma: Application to in vivo pharmacokinetics after pulmonary artery chemoembolization using drug eluting beads. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2010, 878, 738-742.	2.3	18
25	Minimally invasive image-guided therapy for inoperable hepatocellular carcinoma: What is the evidence today?. Insights Into Imaging, 2010, 1, 167-181.	3.4	21
26	Doxorubicin and irinotecan drug-eluting beads for treatment of glioma: a pilot study in a rat model. Journal of Materials Science: Materials in Medicine, 2010, 21, 1393-1402.	3.6	27
29	Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocellular carcinoma (HCC). Journal of Surgical Oncology, 2010, 101, 476-480.	1.7	196
30	Local implantation of doxorubicin drug eluting beads in rat glioma. International Journal of Pharmaceutics, 2010, 402, 184-189.	5.2	20
31	Endovascular Techniques in Palliative Care. Clinical Oncology, 2010, 22, 771-780.	1.4	12
32	Prognostic factors for survival in patients with unresectable hepatocellular carcinoma undergoing chemoembolization with doxorubicin drug-eluting beads: a preliminary study. Hpb, 2010, 12, 174-180.	0.3	43
33	Longterm follow-up after transarterial chemotherapy for hepatocellular carcinoma in a Scandinavian centre. Hpb, 2010, 12, 637-643.	0.3	8
34	Review article: the management of hepatocellular carcinoma. Alimentary Pharmacology and Therapeutics, 2010, 31, 461-476.	3.7	174
35	Transarterial embolisation of hepatocellular carcinoma with doxorubicin-eluting beads: single centre early experience. Biomedical Imaging and Intervention Journal, 2010, 6, e7.	0.5	16
36	Advances in image-guided intratumoral drug delivery techniques. Therapeutic Delivery, 2010, 1, 307-322.	2.2	23
37	Treatment of Intermediate/Advanced Hepatocellular Carcinoma in the Clinic: How Can Outcomes Be Improved?. Oncologist, 2010, 15, 42-52.	3.7	133
38	Development of "Imageable" Beads for Transcatheter Embolotherapy. Journal of Vascular and Interventional Radiology, 2010, 21, 865-876.	0.5	78
39	Arterial Patency after Repeated Hepatic Artery Bland Particle Embolization. Journal of Vascular and Interventional Radiology, 2010, 21, 522-526.	0.5	34
41	Neuroradiologie et radiologie digestive interventionnelles. Actualites Pharmaceutiques Hospitalieres, 2010, 6, 47-50.	0.1	0
42	Conventional versus Doxorubicin-eluting Bead Transarterial Chemoembolization for Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology, 2011, 22, 1545-1552.	0.5	203

#	ARTICLE	IF	CITATIONS
43	Asian Consensus Workshop Report: Expert Consensus Guideline for the Management of Intermediate and Advanced Hepatocellular Carcinoma in Asia. <i>Oncology</i> , 2011, 81, 158-164.	1.9	104
44	Chimio-embolisation trans-artérielle des carcinomes hépatocellulaires par billes chargées à la doxorubicine. Transarterial chemoembolization of hepatocellular carcinoma with doxorubicin eluting beads. <i>Journal of Medical Imaging and Radiation Sciences</i> , 2011, 42, 21-31.	0.3	0
46	Experience Using Doxorubicin-Loaded DC Beads® During Hepatic Chemoembolisation. <i>Farmacia Hospitalaria (English Edition)</i> , 2011, 35, 172-179.	0.0	0
47	Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: Radiologic-pathologic correlation. <i>Journal of Hepatology</i> , 2011, 54, 695-704.	3.7	140
48	Embolization of hepatocellular carcinoma with drug-eluting beads: Doxorubicin tissue concentration and distribution in patient liver explants. <i>Journal of Hepatology</i> , 2011, 55, 1332-1338.	3.7	150
49	Comparative study of cisplatin and epirubicin in transcatheter arterial chemoembolization for hepatocellular carcinoma. <i>Hepatology Research</i> , 2011, 41, 303-309.	3.4	17
50	Transarterial Chemoembolization of Child-A hepatocellular carcinoma: Drug-eluting bead TACE (DEB) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	2.1	68
52	Lipid Nanocapsules Loaded with Rhenium-188 Reduce Tumor Progression in a Rat Hepatocellular Carcinoma Model. <i>PLoS ONE</i> , 2011, 6, e16926.	2.5	38
53	Chemoembolization for Hepatocellular Carcinoma. <i>Seminars in Roentgenology</i> , 2011, 46, 105-114.	0.6	4
54	Trans-arterial chemoembolization as a therapy for liver tumours: New clinical developments and suggestions for combination with angiogenesis inhibitors. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 80, 40-53.	4.4	63
56	Transcatheter Arterial Chemoembolization for Liver Cancer: Is It Time to Distinguish Conventional from Drug-Eluting Chemoembolization?. <i>CardioVascular and Interventional Radiology</i> , 2011, 34, 37-49.	2.0	96
57	Safety Profile of Sequential Transcatheter Chemoembolization with DC Bead®, [®] : Results of 237 Hepatocellular Carcinoma (HCC) Patients. <i>CardioVascular and Interventional Radiology</i> , 2011, 34, 774-785.	2.0	120
58	Severe Complication After a Doxorubicin-Eluting-Bead Embolization: Surgical Management and Pathological Findings. <i>CardioVascular and Interventional Radiology</i> , 2011, 34, 186-189.	2.0	2
59	Transcatheter Arterial Chemoembolization with Epirubicin-Loaded Superabsorbent Polymer Microspheres for 135 Hepatocellular Carcinoma Patients: Single-Center Experience. <i>CardioVascular and Interventional Radiology</i> , 2011, 34, 557-565.	2.0	54
60	September 10-14 Munich, Germany CIRSE 2011. <i>CardioVascular and Interventional Radiology</i> , 2011, 34, 331-7.	2.0	10
61	Hepatic and biliary damage after transarterial chemoembolization for malignant hepatic tumors: Incidence, diagnosis, treatment, outcome and mechanism. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 79, 164-174.	4.4	58
62	Drug delivery embolization systems: a physician's perspective. <i>Expert Opinion on Drug Delivery</i> , 2011, 8, 1071-1084.	5.0	15
63	New Insights into the Mechanisms of the Interactions Between Doxorubicin and the Ion-Exchange Hydrogel DC Bead®, [®] for Use in Transarterial Chemoembolization (TACE). <i>Journal of Biomaterials Science, Polymer Edition</i> , 2012, 23, 333-354.	3.5	33

#	ARTICLE	IF	CITATIONS
64	Current status of embolic agents for liver tumor embolization. International Journal of Clinical Oncology, 2012, 17, 306-315.	2.2	67
65	Acute ischemic cholecystitis after transarterial chemoembolization with drug-eluting beads. Clinical Imaging, 2012, 36, 861-864.	1.5	8
66	Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. Journal of Hepatology, 2012, 57, 1244-1250.	3.7	220
67	Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. Journal of Hepatology, 2012, 56, 1330-1335.	3.7	436
68	Transarterial chemoembolization in very early and early-stage hepatocellular carcinoma patients excluded from curative treatment: A prospective cohort study. European Journal of Radiology, 2012, 81, 1173-1178.	2.6	92
69	Transarterial RAdioembolization versus ChemoEmbolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial. Trials, 2012, 13, 144.	1.6	27
70	Locoregional radiological treatment for hepatocellular carcinoma; Which, when and how?. Cancer Treatment Reviews, 2012, 38, 54-62.	7.7	57
71	Midterm follow-up after DC-BEAD,±TACE of Hepatocellular Carcinoma (HCC). European Journal of Radiology, 2012, 81, 3857-3861.	2.6	13
72	Response rate and clinical outcome of HCC after first and repeated cTACE performed "on demand". Journal of Hepatology, 2012, 57, 1258-1267.	3.7	126
73	Radiopaque Drug-Eluting Beads for Transcatheter Embolotherapy: Experimental Study of Drug Penetration and Coverage in Swine. Journal of Vascular and Interventional Radiology, 2012, 23, 257-264.e4.	0.5	109
74	Safety and Feasibility of Same-day Discharge of Patients with Unresectable Hepatocellular Carcinoma Treated with Doxorubicin Drug-eluting Bead Transcatheter Chemoembolization. Journal of Vascular and Interventional Radiology, 2012, 23, 1286-1293.e1.	0.5	26
75	Transcatheter Treatment of Hepatocellular Carcinoma with Doxorubicin-loaded DC Bead (DEBDOX): Technical Recommendations. CardioVascular and Interventional Radiology, 2012, 35, 980-985.	2.0	243
76	Chemoembolization With Doxorubicin-Eluting Beads for Unresectable Hepatocellular Carcinoma: Five-Year Survival Analysis. CardioVascular and Interventional Radiology, 2012, 35, 1119-1128.	2.0	176
78	Hepatocellular carcinoma. European Journal of Gastroenterology and Hepatology, 2012, 24, 1.	1.6	14
79	Interventional therapies for hepatocellular carcinoma. Cancer Imaging, 2012, 12, 79-88.	2.8	26
80	Stereotactic body radiation therapy in hepatocellular carcinoma and cirrhosis: Evaluation of radiological and pathological response. Journal of Surgical Oncology, 2012, 105, 692-698.	1.7	76
81	Hepatic artery embolization and chemoembolization of liver tumors. , 2012, , 1344-1361.e3.		0
82	Radiological response predicts survival following transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma. Alimentary Pharmacology and Therapeutics, 2012, 35, 1343-1350.	3.7	83

#	ARTICLE	IF	CITATIONS
83	Comparison of the Anti-tumor Effects of Two Platinum Agents (Miriaplatin and Fine-Powder Cisplatin). CardioVascular and Interventional Radiology, 2012, 35, 399-405.	2.0	13
84	Investigation of the mechanisms governing doxorubicin and irinotecan release from drug-eluting beads: mathematical modeling and experimental verification. Journal of Materials Science: Materials in Medicine, 2013, 24, 2359-2370.	3.6	31
85	Feasibility, safety and pharmacokinetic study of hepatic administration of drug-eluting beads loaded with irinotecan (DEBIRI) followed by intravenous administration of irinotecan in a porcine model. Journal of Materials Science: Materials in Medicine, 2013, 24, 115-127.	3.6	17
86	Antitumor effect of miriaplatin-lipiodol suspension/emulsion using a VX2 liver tumor model. Japanese Journal of Radiology, 2013, 31, 662-667.	2.4	2
87	Predisposing Factors of Hepatocellular Carcinoma Recurrence Following Complete Remission in Response to Transarterial Chemoembolization. Digestive Diseases and Sciences, 2013, 58, 1758-1765.	2.3	27
88	Peripheral Applications of Drug-Coated Balloons: Past, Present and Future. CardioVascular and Interventional Radiology, 2013, 36, 281-291.	2.0	28
89	Phase II Study of Chemoembolization With Drug-Eluting Beads in Patients With Hepatic Neuroendocrine Metastases: High Incidence of Biliary Injury. CardioVascular and Interventional Radiology, 2013, 36, 449-459.	2.0	91
90	Factors Affecting Survival following Chemoembolization with Doxorubicin-eluting Microspheres for Inoperable Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology, 2013, 24, 257-265.	0.5	10
91	Safety and Efficacy of Doxorubicin Drug-eluting Bead Transarterial Chemoembolization in Patients with Advanced Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology, 2013, 24, 307-315.	0.5	68
92	Doxorubicin-loaded drug-eluting beads (DC Bead®) for use in transarterial chemoembolization: A stability assessment. Journal of Oncology Pharmacy Practice, 2013, 19, 65-74.	0.9	23
93	Quantification and Reduction of Reflux during Embolotherapy Using an Antireflux Catheter and Tantalum Microspheres: Ex Vivo Analysis. Journal of Vascular and Interventional Radiology, 2013, 24, 575-580.	0.5	31
94	1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) chemoembolization (TACE) for treatment of bulky uveal melanoma (UM) hepatic metastases. Journal of Vascular and Interventional Radiology, 2013, 24, S12-S13.	0.5	0
95	New progress of non-surgical treatments for hepatocellular carcinoma. Medical Oncology, 2013, 30, 381.	2.5	25
96	Gelatin Microspheres: Correlation between Embolic Effect/Degradability and Cross-linkage/Particle Size. CardioVascular and Interventional Radiology, 2013, 36, 1105-1111.	2.0	7
97	Effectiveness and safety of doxorubicin loaded beads in hepatocellular carcinoma. International Journal of Clinical Pharmacy, 2013, 35, 1105-1112.	2.1	2
98	Toxicity of Doxorubicin on Pig Liver After Chemoembolization with Doxorubicin-loaded Microspheres: A Pilot DNA-microarrays and Histology Study. CardioVascular and Interventional Radiology, 2013, 36, 204-212.	2.0	11
99	Multidisciplinary Management of Hepatocellular Carcinoma: Where Are We Today?. Seminars in Liver Disease, 2013, 33, S3-S10.	3.6	32
101	Chemoembolization with drug-eluting microspheres (DEM-TACE) for hepatocellular carcinoma: single-center review of safety and efficacy. Journal of Hepatocellular Carcinoma, 2014, 1, 187.	3.7	6

#	ARTICLE	IF	CITATIONS
102	Interventional treatment for unresectable hepatocellular carcinoma. World Journal of Gastroenterology, 2014, 20, 13453.	3.3	39
103	Survival, Efficacy, and Safety of Small Versus Large Doxorubicin Drug-Eluting Beads TACE Chemoembolization in Patients With Unresectable HCC. American Journal of Roentgenology, 2014, 203, W706-W714.	2.2	66
104	Treatment of intermediate stage hepatocellular carcinoma: a review of intrahepatic doxorubicin drug-delivery systems. Therapeutic Delivery, 2014, 5, 447-466.	2.2	30
105	Conventional TACE and Drug-Eluting Bead TACE as Locoregional Therapy Before Orthotopic Liver Transplantation. Transplantation, 2014, 98, 781-787.	1.0	32
106	Chemoembolization of Hepatocellular Carcinoma with Hepasphere 30â€“60Âµm. Safety and Efficacy Study. CardioVascular and Interventional Radiology, 2014, 37, 165-175.	2.0	97
107	Review of the Impact of Antineoplastic Therapies on the Risk for Cholelithiasis and Acute Cholecystitis. Annals of Surgical Oncology, 2014, 21, 240-247.	1.5	18
108	Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. British Journal of Cancer, 2014, 111, 255-264.	6.4	480
109	Doxorubicinâ€eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 920-925.	2.8	98
110	Transarterial chemoembolization using drug eluting beads and subsequent percutaneous MR-guided radiofrequency ablation in the therapy of intermediate sized hepatocellular carcinoma. European Journal of Radiology, 2014, 83, 1793-1798.	2.6	18
111	TACE performed in patients with a single nodule of Hepatocellular Carcinoma. BMC Cancer, 2014, 14, 601.	2.6	36
112	Safety and Efficacy of a Circumferential Clip-Based Vascular Closure Device in Cirrhotic and Coagulopathic Patients with Hepatocellular Carcinoma After Doxorubicin Drug-eluting Beads Transarterial Chemoembolization. CardioVascular and Interventional Radiology, 2014, 37, 664-670.	2.0	7
113	Transarterial chemoembolization for hepatocellular carcinoma with drug-eluting microspheres. Egyptian Journal of Radiology and Nuclear Medicine, 2014, 45, 761-769.	0.6	1
114	Transferrin targeted core-shell nanomedicine for combinatorial delivery of doxorubicin and sorafenib against hepatocellular carcinoma. Nanomedicine: Nanotechnology, Biology, and Medicine, 2014, 10, 1649-1659.	3.3	82
115	Chemoembolization with DC Beadâ„¢ for the treatment of hepatocellular carcinoma: an update. Hepatic Oncology, 2014, 1, 205-214.	4.2	4
116	Predictors of hepatic decompensation after TACE for hepatocellular carcinoma. BMJ Open Gastroenterology, 2015, 2, e000032.	2.7	28
117	Transarterial chemoembolization with drugâ€eluting beads is effective for the maintenance of the Milanâ€in status in patients with a small hepatocellular carcinoma. Liver Transplantation, 2015, 21, 1259-1269.	2.4	35
118	Advances in endovascular therapy to treat primary hepatocellular carcinoma. Drug Discoveries and Therapeutics, 2015, 9, 342-351.	1.5	7
120	Transarterial chemoembolization using drug eluting beads for the treatment of hepatocellular carcinoma: Now and future. Clinical and Molecular Hepatology, 2015, 21, 344.	8.9	28

#	ARTICLE	IF	CITATIONS
121	Treatment of hepatocellular carcinoma: beyond international guidelines. Liver International, 2015, 35, 129-138.	3.9	93
122	Trans-arterial chemoembolization with doxorubicin-eluting particles versus conventional trans-arterial chemoembolization in unresectable hepatocellular carcinoma: A study of effectiveness, safety and costs. Radiologia, 2015, 57, 496-504.	0.5	15
123	Transarterial Hepatic Chemoembolization with 70-150 µm Drug-Eluting Beads: Assessment of Clinical Safety and Liver Toxicity Profile. Journal of Vascular and Interventional Radiology, 2015, 26, 965-971.	0.5	35
124	Locoregional Therapy of Hepatocellular Carcinoma. Clinics in Liver Disease, 2015, 19, 401-420.	2.1	28
125	Quimioembolización transarterial con partículas liberadoras de doxorubicina frente a quimioembolización transarterial convencional en carcinomas hepatocelulares irresecables: un estudio de eficacia, seguridad y gastos. Radiologia, 2015, 57, 496-504.	0.5	23
126	Small Versus Large-Sized Drug-Eluting Beads (DEBIRI) for the Treatment of Hepatic Colorectal Metastases: A Propensity Score Matching Analysis. CardioVascular and Interventional Radiology, 2015, 38, 361-371.	2.0	37
127	Systematic review of catheter-based intra-arterial therapies in hepatocellular carcinoma: state of the art and future directions. British Journal of Radiology, 2015, 88, 20140564.	2.2	26
128	Systematic review comparing the safety and efficacy of conventional and drug-eluting bead transarterial chemoembolization for inoperable hepatocellular carcinoma. Hepatology Research, 2015, 45, 190-200.	3.4	73
129	Management of hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology, 2015, 141, 861-876.	2.5	92
130	Transarterial chemoembolization with drug-eluting beads in hepatocellular carcinoma. World Journal of Gastroenterology, 2016, 22, 8853.	3.3	31
131	Pharmacokinetics, Safety, and Efficacy of Chemoembolization with Doxorubicin-Loaded Tightly Calibrated Small Microspheres in Patients with Hepatocellular Carcinoma. CardioVascular and Interventional Radiology, 2016, 39, 1379-1391.	2.0	29
132	Treatment of hepatocellular carcinoma: beyond international guidelines. Liver International, 2016, 36, 124-129.	3.9	67
133	TACE vs DEB-TACE: Who wins?. Digestive and Liver Disease, 2016, 48, 796-797.	0.9	10
134	Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial. Journal of Hepatology, 2016, 64, 1090-1098.	3.7	567
135	Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone. Journal of Clinical Oncology, 2016, 34, 2046-2053.	1.6	307
136	DC BeadML: towards an optimal transcatheter hepatic tumour therapy. Journal of Materials Science: Materials in Medicine, 2016, 27, 13.	3.6	35
137	Should we routinely use DEBTACE for unresectable HCC? cTACE versus DEBTACE: a single-center survival analysis. Updates in Surgery, 2017, 69, 67-73.	2.0	15
138	In Vivo Drug Delivery Performance of Lipiodol-Based Emulsion or Drug-Eluting Beads in Patients with Hepatocellular Carcinoma. Molecular Pharmaceutics, 2017, 14, 448-458.	4.6	30

#	ARTICLE	IF	CITATIONS
139	Role of low-molecular-weight heparins in prevention of thromboembolic complication after transarterial chemoembolization in hepatocellular carcinoma. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 317-321.	1.6	30
140	Choice of Intra-arterial Therapy for Hepatocellular Carcinoma: Evidence and Future Horizons. <i>Digestive Disease Interventions</i> , 2017, 01, 105-114.	0.2	1
141	Short-term efficacy of transarterial chemoembolization with epirubicin-loaded superabsorbent polymer microspheres for hepatocellular carcinoma: comparison with conventional transarterial chemoembolization. <i>Abdominal Radiology</i> , 2017, 42, 612-619.	2.1	7
142	Computed tomographic perfusion imaging for the prediction of response and survival to transarterial chemoembolization of hepatocellular carcinoma. <i>Radiology and Oncology</i> , 2017, 52, 14-22.	1.7	11
143	Sustained multiple organ ischaemia after transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. <i>Experimental and Therapeutic Medicine</i> , 2017, 15, 1479-1483.	1.8	7
144	Hepatic artery embolization and chemoembolization of liver tumors. , 2017, , 1398-1416.e4.		0
145	Chemoembolization of liver cancer with drug-loading microsphere 50-100µm. <i>Oncotarget</i> , 2017, 8, 5392-5399.	1.8	13
146	Challenges in chemotherapy delivery: comparison of standard chemotherapy delivery to locoregional vascular mass fluid transfer. <i>Future Oncology</i> , 2018, 14, 647-663.	2.4	23
147	Safety and Feasibility of Chemoembolization with Doxorubicin-Loaded Small Calibrated Microspheres in Patients with Hepatocellular Carcinoma: Results of the MIRACLE I Prospective Multicenter Study. <i>CardioVascular and Interventional Radiology</i> , 2018, 41, 587-593.	2.0	40
148	The integration of pharmacology and pathophysiology into locoregional chemotherapy delivery via mass fluid transfer. <i>Journal of Controlled Release</i> , 2018, 292, 18-28.	9.9	2
149	DEB-TACE: a standard review. <i>Future Oncology</i> , 2018, 14, 2969-2984.	2.4	76
150	Survival Outcomes of Very Small Drug-Eluting Beads Used in Chemoembolization of Unresectable Hepatocellular Carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2019, 30, 1325-1334.e2.	0.5	15
151	Survival, tumour response and safety of 70µm versus 100µm doxorubicin drug-eluting beads in transarterial chemoembolisation for hepatocellular carcinoma. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2019, 63, 802-811.	1.8	17
152	Radiological appearance of hepatocellular carcinoma predicts the response to trans-arterial chemoembolization in patients undergoing liver transplantation. <i>BMC Cancer</i> , 2019, 19, 1041.	2.6	13
153	Advances in Biomaterials and Technologies for Vascular Embolization. <i>Advanced Materials</i> , 2019, 31, e1901071.	21.0	133
154	Risk factors for local recurrence of hepatocellular carcinoma after transcatheter arterial chemoembolization with drug-eluting beads (DEB-TACE). <i>Japanese Journal of Radiology</i> , 2019, 37, 543-548.	2.4	13
155	Laboratory and Imaging Prognostic Indicators following Arterial Locoregional Therapies for Hepatocellular Carcinoma Survival. <i>Journal of Vascular and Interventional Radiology</i> , 2019, 30, 1893-1894.	0.5	0
156	Conventional Versus Small Doxorubicin-eluting Bead Transcatheter Arterial Chemoembolization for Treating Barcelona Clinic Liver Cancer Stage 0/A Hepatocellular Carcinoma. <i>CardioVascular and Interventional Radiology</i> , 2020, 43, 55-64.	2.0	24

#	ARTICLE	IF	CITATIONS
157	Contemporary Techniques and Applications of Radioembolization in Patients with Hepatocellular Carcinoma. <i>Advances in Clinical Radiology</i> , 2020, 2, 113-125.	0.2	2
158	Transarterial chemoembolization with drug-eluting beads in patients with hepatocellular carcinoma: response analysis with mRECIST. <i>Diagnostic and Interventional Radiology</i> , 2021, 27, 85-93.	1.5	3
159	Comparison of the efficacy and safety of conventional transarterial chemoembolization with and without drug-eluting beads embolization for the treatment of unresectable large hepatocellular carcinoma. <i>Hepatology Research</i> , 2021, 51, 482-489.	3.4	6
160	Drug-eluting beads TACE is safe and non-inferior to conventional TACE in HCC patients with TIPS. <i>European Radiology</i> , 2021, 31, 8291-8301.	4.5	15
161	The short-term safety and efficacy of TANDEM microspheres of various sizes and doxorubicin loading concentrations for hepatocellular carcinoma treatment. <i>Scientific Reports</i> , 2021, 11, 12277.	3.3	5
162	Effect of Transarterial Chemoembolization on ALBI Grade in Intermediate-Stage Hepatocellular Carcinoma: Criteria for Unsuitable Cases Selection. <i>Cancers</i> , 2021, 13, 4325.	3.7	8
163	Does Drug-Eluting Bead Transcatheter Arterial Chemoembolization Improve the Management of Patients with Hepatocellular Carcinoma? A Meta-Analysis. <i>PLoS ONE</i> , 2014, 9, e102686.	2.5	24
164	Efficacy and Safety of Drug Eluting Bead TACE with Microspheres $\leq 150\ \mu\text{m}$ for the Treatment of Hepatocellular Carcinoma. <i>Anticancer Research</i> , 2018, 38, 1025-1032.	1.1	8
165	The usefulness of contrast-enhanced ultrasonography in the early detection of hepatocellular carcinoma viability after transarterial chemoembolization: pilot study. <i>Clinical and Molecular Hepatology</i> , 2015, 21, 165.	8.9	19
166	Extravascular use of drug-eluting beads: A promising approach in compartment-based tumor therapy. <i>World Journal of Gastroenterology</i> , 2013, 19, 7586.	3.3	2
167	Locoregional treatments for hepatocellular carcinoma: Current evidence and future directions. <i>World Journal of Gastroenterology</i> , 2019, 25, 4614-4628.	3.3	77
168	Safety Profile and Efficacy of Chemoembolization with Doxorubicin - Loaded Polyethylene Glycol Microspheres in Patients with Hepatocellular Carcinoma. <i>Open Access Macedonian Journal of Medical Sciences</i> , 2019, 7, 742-746.	0.2	4
169	Doxorubicin-loaded drug-eluting beads versus conventional transarterial chemoembolization for nonresectable hepatocellular carcinoma. <i>Saudi Journal of Gastroenterology</i> , 2015, 21, 175.	1.1	40
170	Efficacy of intra-arterial contrast-enhanced ultrasonography during transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. <i>World Journal of Hepatology</i> , 2018, 10, 95-104.	2.0	8
171	Transarterial chemoembolization for treatment of hepatocellular carcinoma: A single center experience. <i>Turkish Journal of Gastroenterology</i> , 2013, 24, 141-147.	1.1	6
172	Hepatocellular carcinoma treated with transarterial chemoembolization: Evaluation with parametric contrast-enhanced ultrasonography. <i>World Journal of Radiology</i> , 2012, 4, 379.	1.1	12
173	Saudi Guidelines for the Diagnosis and Management of Hepatocellular Carcinoma: Technical Review and Practice Guidelines. <i>Annals of Saudi Medicine</i> , 2012, 32, 174-199.	1.1	26
174	Medical Therapy of HCC. , 2009, , 527-568.		0

#	ARTICLE	IF	CITATIONS
176	Percutaneous Interventional Technique for Intra-arterial Chemoembolization. , 2009, , 569-588.		0
177	A case of hepatocellular carcinoma in the caudate lobe successfully treated by transcatheter arterial chemoembolization using drug-eluting beads. The Korean Journal of Hepatology, 2010, 16, 405.	1.5	1
179	Emerging Therapies for Hepatocellular Carcinoma. , 2012, , 263-290.		0
180	Transarterial Chemoembolization for HCC with Drug-Eluting Microspheres. , 0, , .		0
181	Advances in the Interventional Therapies for Hepatocellular Carcinoma. , 2012, , 205-219.		0
182	A Multidisciplinary Approach for the Treatment of Intermediated to Advanced Hepatocellular Carcinoma “Is it Still Optional?”. Journal of Liver, 2013, 02, .	0.3	0
183	Response rates of hepatocellular carcinoma and hepatic colorectal cancer metastases to drug eluting bead regional liver therapy. Hepatoma Research, 2017, 3, .	1.5	0
184	Gastrointestinal Interventions: Then and Now. Digestive Disease Interventions, 2020, 04, 401-408.	0.2	0
185	Transarterial chemoembolization with Doxorubicin-eluting microspheres for inoperable hepatocellular carcinoma. Gastrointestinal Cancer Research: GCR, 2011, 4, 2-8.	0.7	12
186	Doxorubicin-eluting beads versus conventional transarterialchemoembolization for the treatment of hepatocellular carcinoma: a meta-analysis. International Journal of Clinical and Experimental Medicine, 2014, 7, 3892-903.	1.3	15
187	Hepatocellular carcinoma locoregional therapies: Outcomes and future horizons. World Journal of Gastroenterology, 2021, 27, 7462-7479.	3.3	24
188	⁹⁰ Y Radioembolization versus Drug-eluting Bead Chemoembolization for Unresectable Hepatocellular Carcinoma: Results from the TRACE Phase II Randomized Controlled Trial. Radiology, 2022, 303, 699-710.	7.3	74
189	Locoregional Therapies for Hepatocellular Carcinoma. , 2022, , 307-324.		0
190	Salvage locoregional therapies for recurrent hepatocellular carcinoma. World Journal of Gastroenterology, 0, 29, 413-424.	3.3	4
191	Safety, Efficacy and Distribution of Doxorubicin Loaded Radiopaque Beads in Chemoembolization in Intermediate Stage Hepatocellular Carcinoma (HCC) with Correlation with Local Response. CardioVascular and Interventional Radiology, 2023, 46, 337-349.	2.0	1
192	Rationale, Definition, and History of Transarterial Chemoembolization. , 2023, , 1-9.		0
193	Particle and Chemoembolization for Primary Liver Cancer. , 2023, , 1-15.		0